Spironolactone effects on myocardium changes induced by thyroid hormone in rats;Efeitos da espironolactona sobre as alterações miocárdicas induzidas pelo hormônio tireoideano em ratos

Arquivos Brasileiros de Cardiologia

Volumn 89, Issue 6, 2007, Pages

  Fernandes, Maria Luiza Mendonça Pereira ^a,b   Ferro, Eloísa Amália Vieira ^a   Beletti, Marcelo Emilio ^a   Resende, Elmiro Santos ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiomegaly; Myocardium; Spironolactone; Thyroxine; Ventricular remodeling

Indexed keywords

ALDOSTERONE; LEVOTHYROXINE SODIUM; SPIRONOLACTONE; THYROID HORMONE; ALDOSTERONE ANTAGONIST; LIOTHYRONINE; THYROXINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; DILUTION; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE; HEART MUSCLE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOMETRY; HORMONE DETERMINATION; MALE; MORPHOLOGY; MUSCLE CELL; NONHUMAN; RAT; SINGLE DRUG DOSE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; HEART LEFT VENTRICLE HYPERTROPHY; ORGAN SIZE; WISTAR RAT;

ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; HEART; HEART RATE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MODELS, ANIMAL; ORGAN SIZE; RATS; RATS, WISTAR; SPIRONOLACTONE; THYROID HORMONES; THYROXINE; TRIIODOTHYRONINE;

EID: 41149134889     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007001800008     Document Type: Article

References (37)

1. Parry CH. Collections from the Unpublished Medical Writings of the Late Calef Hillies Parry. London: Underwoods; 1825. p. 478.
2. Dillmann WH. Thyroid hormone and the heart. Thyroid Today. 1983; 4 (2): 1-6.
3. Piatnek-Leunissen D, Olson RE. Cardiac failure in the dog as a consequence of exogenous hyperthyroidism. Circ Res. 1967; 20: 242-52.
4. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am. 1998; 27 (1): 51-62.
5. Zak R. Cell proliferation during cardiac growth. Am.J Cardiol. 1973; 31: 211-9.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991; 83: 1849-65.
7. Batlouni M. Hipertrofia cardíaca: fatores determinantes e mecanismos moleculares. Arq Bras Cardiol. 1995; 65(6): 533-9.
8. Sanford CF, Griffin EE, Wildenthal K. Synthesis and degradation of myocardial protein during the development and regression of thyroxine-induced cardiac hypertrophy in rats. Circ Res. 1978; 43 (5): 688-94.
9. Ojamaa K, Balkman C, Klein IL. Acute effects of thriiodothyronine on arterial smooth muscle cells. Ann Thorac Surg. 1993; 56 (Suppl.1): S61-7.
10. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994; 331 (13): 847-53.
11. Caiozzo VJ, Baker MJ, McCue SA, Baldwin KM. Single-fiber and whose muscle analyses of MHC isoform plasticity: interaction between T3 and unloading. Am J Physiol. 1997; 273 (3 Pt 1): C944-52.
12. Klemperer JD, Ojamaa K, Klein I. Thyroid hormone therapy in cardiovascular disease. Prog Cardiovasc Dis. 1996; 38 (4): 329-36.
13. Klein I. Thyroid hormone and cardiovascular system. Am J Med. 1990; 88: 631-7.
14. Dillman WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990; 88: 627-30.
15. Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J. 1998; 135: 187-96.
16. Shirani J, Barron MM, Pierre-Louis, MY, Roberts WC. Congestive heart failure, dilated cardiac ventricules, and sudden death in hyperthyroidism. Am J Cardiol. 1993; 72: 365-8.
17. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993; 71: 12A-16A.
18. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative Sandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316 (23): 1429-35.
19. Swedberg K, Eneroth P, Kjekshys J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with sever congestive heart failure and their relation to mortality. Circulation. 1990; 82: 1730-6.
20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl J Med. 1999; 341 (2): 709-17.
21. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardium infarction. N Engl J Med. 2003; 348: 1309-21.
22. Mill JG, Milanez Mda C, de Resende MM, Gomes Mda G, Leite CM. Spironolactone preventes cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol. 2003; 30 (10): 739-44.
23. Cuttadini A, Serpico R, Monti MG, Sacca L. The role of aldosterone in the development of postinfarction fibrosis. Ital Heart J. 2005; 6 (Suppl 1) S43-50.
24. Klein I. Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol. Endocrinology. 1988; 123 (1): 203-10.
25. Sanford CF, Griffin EE, Wildenthal K. Synthesis and degradation of miocardial protein during the development and regression of thyroxine-induced cardiac hypertrophy in rats. Circ Res. 1978; 43 (5): 689-94.
26. Zierhut W, Zimmer HG. Triiodothyronine-induced changes in function, metabolism and weight of the rat heart: effects of α- and β-adrenergic blockade. Basic Res Cardiol. 1989; 84: 359-70,
27. Bedotto JB, Gay RG, Grahan SD, Morkin E, Goldman S. Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade. J Pharmacol Exp Ther. 1989; 248 (2): 632-6.
28. Heide SM, Visser TJ, Everts ME, Klaren PHM. Metabolism of thyroid hormones in cultured cardiac fibroblasts of neonatal rats. J Endocrinol. 2002; 174: 111-9.
29. Page E, McCallister LP. Quantitative electron microscopic description of heart muscle cells: application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol. 1973; 31: 172-81.
30. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol. 2002; 34 (12): 1577-84.
31. Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol. 1993; 71 (3): 46A-54A.
32. Murga C, Fukuhara S, Gutkind JS. Novel molecular mediators in the pathway connecting G-protein-coupled receptors to MAP kinase cascades. Trends Endocrinol Metab. 1999; 10 (4): 122-7.
33. Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003; 87 (2): 441-57.
34. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in lowal-dosterone hypertensive rats. Hypertension. 2006; 47 (4): 634-5.
35. Funder JS. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005; 93: 121-5.
36. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006; 47 (4): 671-9.
37. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004; 217 (1-2): 53-8.